375 related articles for article (PubMed ID: 21649691)
1. Anti-platelet therapy: phosphodiesterase inhibitors.
Gresele P; Momi S; Falcinelli E
Br J Clin Pharmacol; 2011 Oct; 72(4):634-46. PubMed ID: 21649691
[TBL] [Abstract][Full Text] [Related]
2. Targeting phosphodiesterases in anti-platelet therapy.
Rondina MT; Weyrich AS
Handb Exp Pharmacol; 2012; (210):225-38. PubMed ID: 22918733
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of satigrel (E5510), a new anti-platelet drug, in inhibiting human platelet aggregation. Selectivity and potency against prostaglandin H synthases isozyme activities and phosphodiesterase isoform activities.
Nagakura N; Saeki T; Harada K; Yoshitake S; Kobayashi S; Yamanaka T; Saito I
Biol Pharm Bull; 1996 Jun; 19(6):828-33. PubMed ID: 8799481
[TBL] [Abstract][Full Text] [Related]
4. Phosphorylation of the vasodilator-stimulated phosphoprotein (VASP) by the anti-platelet drug, cilostazol, in platelets.
Sudo T; Ito H; Kimura Y
Platelets; 2003 Sep; 14(6):381-90. PubMed ID: 14602552
[TBL] [Abstract][Full Text] [Related]
5. Cilostazol and dipyridamole synergistically inhibit human platelet aggregation.
Liu Y; Cone J; Le SN; Fong M; Tao L; Shoaf SE; Bricmont P; Czerwiec FS; Kambayashi J; Yoshitake M; Sun B
J Cardiovasc Pharmacol; 2004 Aug; 44(2):266-73. PubMed ID: 15243309
[TBL] [Abstract][Full Text] [Related]
6. Differential regulation of human platelet responses by cGMP inhibited and stimulated cAMP phosphodiesterases.
Manns JM; Brenna KJ; Colman RW; Sheth SB
Thromb Haemost; 2002 May; 87(5):873-9. PubMed ID: 12038792
[TBL] [Abstract][Full Text] [Related]
7. Control of platelet activation by cyclic AMP turnover and cyclic nucleotide phosphodiesterase type-3.
Feijge MA; Ansink K; Vanschoonbeek K; Heemskerk JW
Biochem Pharmacol; 2004 Apr; 67(8):1559-67. PubMed ID: 15041473
[TBL] [Abstract][Full Text] [Related]
8. Characterization of the isoenzymes of cyclic nucleotide phosphodiesterase in human platelets and the effects of E4021.
Ito M; Nishikawa M; Fujioka M; Miyahara M; Isaka N; Shiku H; Nakano T
Cell Signal; 1996 Dec; 8(8):575-81. PubMed ID: 9115850
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the effects of cilostazol and milrinone on intracellular cAMP levels and cellular function in platelets and cardiac cells.
Cone J; Wang S; Tandon N; Fong M; Sun B; Sakurai K; Yoshitake M; Kambayashi J; Liu Y
J Cardiovasc Pharmacol; 1999 Oct; 34(4):497-504. PubMed ID: 10511123
[TBL] [Abstract][Full Text] [Related]
10. Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake.
Liu Y; Shakur Y; Yoshitake M; Kambayashi Ji J
Cardiovasc Drug Rev; 2001; 19(4):369-86. PubMed ID: 11830753
[TBL] [Abstract][Full Text] [Related]
11. Dipyridamole synergizes with nitric oxide to prolong inhibition of thrombin-induced platelet shape change.
Jensen BO; Kleppe R; Kopperud R; Nygaard G; Døskeland SO; Holmsen H; Selheim F
Platelets; 2011; 22(1):8-19. PubMed ID: 20958117
[TBL] [Abstract][Full Text] [Related]
12. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro.
Wallis RM; Corbin JD; Francis SH; Ellis P
Am J Cardiol; 1999 Mar; 83(5A):3C-12C. PubMed ID: 10078537
[TBL] [Abstract][Full Text] [Related]
13. Mathematical Modelling of Nitric Oxide/Cyclic GMP/Cyclic AMP Signalling in Platelets.
Kleppe R; Jonassen I; Døskeland SO; Selheim F
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29462984
[TBL] [Abstract][Full Text] [Related]
14. Synergistic effect of cilostazol and dipyridamole mediated by adenosine on shear-induced platelet aggregation.
Nakamura T; Uchiyama S; Yamazaki M; Iwata M
Thromb Res; 2007; 119(4):511-6. PubMed ID: 17046050
[TBL] [Abstract][Full Text] [Related]
15. Differential effects of phosphodiesterase inhibitors on platelet activating factor (PAF)- and adenosine diphosphate (ADP)-induced equine platelet aggregation.
Rickards KJ; Andrews MJ; Waterworth TH; Alexander GB; Cunningham FM
J Vet Pharmacol Ther; 2003 Aug; 26(4):277-82. PubMed ID: 12887610
[TBL] [Abstract][Full Text] [Related]
16. The effect of Sildenafil on human platelet secretory function is controlled by a complex interplay between phosphodiesterases 2, 3 and 5.
Dunkern TR; Hatzelmann A
Cell Signal; 2005 Mar; 17(3):331-9. PubMed ID: 15567064
[TBL] [Abstract][Full Text] [Related]
17. Thrombin regulates intracellular cyclic AMP concentration in human platelets through phosphorylation/activation of phosphodiesterase 3A.
Zhang W; Colman RW
Blood; 2007 Sep; 110(5):1475-82. PubMed ID: 17392505
[TBL] [Abstract][Full Text] [Related]
18. Estimation of anti-platelet drugs on human platelet aggregation with a novel whole blood aggregometer by a screen filtration pressure method.
Sudo T; Ito H; Ozeki Y; Kimura Y
Br J Pharmacol; 2001 Aug; 133(8):1396-404. PubMed ID: 11498527
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of platelet aggregation and the release of P-selectin from platelets by cilostazol.
Kariyazono H; Nakamura K; Shinkawa T; Yamaguchi T; Sakata R; Yamada K
Thromb Res; 2001 Mar; 101(6):445-53. PubMed ID: 11323002
[TBL] [Abstract][Full Text] [Related]
20. The NO/cGMP/PKG pathway in platelets: The therapeutic potential of PDE5 inhibitors in platelet disorders.
Degjoni A; Campolo F; Stefanini L; Venneri MA
J Thromb Haemost; 2022 Nov; 20(11):2465-2474. PubMed ID: 35950928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
